Non-invasive Prenatal DNA Testing (NIPT) is a non-invasive, convenient, accurate, and rapid technology for detecting rapid screening technology for fetal chromosomal aneuplodies, such as trisomy 21 (Down's syndrome), trisomy 18 (Edward's syndrome) and trisomy 13 (Patau's syndrome).
- The gestation week is<12+0;
- One partner in a couple has chromosomal abnormalities;
- The pregnant women have received allogeneic blood transfusion, transplantation, or cell therapy within 1 year;
- Fetal ultrasound examination indicates structural abnormalities that require invasive prenatal diagnosis;
- One or both partners in a couple have a familial history of genetic disease,or high risk of fetal genetic diseases;
- Combined with malignant tumor during pregnancy;
- Other situations that clinicians consider can significantly affect the accuracy of NIPT results.
Except for the inapplicable situations mentioned above, pregnant women and their families can choose NIPT with fully informed consent.